Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AGM

<< Previous

Bullboard Posts

Next >>

Post by inthnoon Apr 12, 2024 6:27pm

161 Views

Post# 35986872

AGM

It would appear that we only get a virtual meeting as I am sure it would be too difficult for management to give shareholders a chance to ask any questions. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual meeting (the “Meeting”) of the holders (“Shareholders”) of common shares of Oncolytics Biotech Inc. (the “Corporation”) will be held as follows: When: Wednesday, May 15, 2024 at 4:00 p.m. (Toronto time) Where: Virtual-only meeting via live audio webcast online at virtual-meetings.tsxtrust.c... Password: onc2024 (case sensitive)

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest